24
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y Guideline.
is resource is a practice tool based on ASCO
®
practice guidelines and is not intended to substitute for
the independent professional judgment of the treating physician. Practice guidelines do not account for
individual variation among patients. is pocket guide does not purport to suggest any particular course of
medical treatment. Use of the practice guidelines and this resource are voluntary. e practice guidelines and
additional information are available at www.asco.org/resource-stratified-guidelines. Copyright ©2020 by
American Society of Clinical Oncolog y. All rights reserved.
Source
E. Gabriela Chiorean, Govind Nandakumar, Temidayo Fadelu, Sarah Temin, Ashley Efrain Alarcon-Rozas,
Suyapa Bejarano, Adina-Emilia Croitoru, Surbhi Grover, Pritesh V. Lohar, Andrew Odhiambo, Se Hoon
Park, Erika Ruiz Garcia, Catherine Teh, Azmina Rose, Bassem Zaki, Mary D. Chamberlin. Treatment of
Patients with Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. JCO Glob Oncol. 2020
March 9 doi: 10.1200/JGO.19.00367
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2020 All rights reserved
ASCOmCRC3203
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/resource-stratified-guidelines.
Abbreviations
anti-EGFR, anti-epidermal growth factor medical therapy; BRAF, BRAF (v-raf murine sarcoma viral
oncogene homolog B1); CEA, carcinoembryonic antigen; CT, computed tomography; dMMR,
deficient mismatch repair; EGFR, epidermal growth factor receptor; HAI, Hepatic arterial infusion;
mCRC, metastatic colorectal cancer; MDT, multidisciplinary team; mRectal, metastatic rectal cancer;
MRI, magnetic resonance imagining ; MSI, microsatellite instability; MSI-H, MSI high; MSI/MMR,
microsatellite instability, MMR, mismatch repair genes; MUT, mutation (or mutated); N/A, not
available; NACT, neoadjuvant chemotherapy; PET/CT, positron emission tomography/computed
tomography; PS, performance status; RAS, RAS gene; SBRT, stereotactic body radiation therapy; SIRT,
selective internal radiation therapy; TACE, trans-arterial chemoembolization; US, ultrasound; V600E,
valine at amino acid 600; VEGF, vascular endothelial growth factor; WT, wild-type
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits
outweigh harms
H High Strong
FC
Formal
consensus
H Harms outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
Ins Insufficient
